MENU

NRIX Stock Nurix Therapeutics (NRIX, $9.53) Stochastic Oscillator left the oversold zone on August 26, 2025

A.I.dvisor
at Tickeron.com
Loading...
NRIX - Nurix Therapeutics
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $9.53
Daily change: -$0.14 (-1.45%)
Daily volume: 620.6K
Capitalization: $728.6M
Industry: Biotechnology
This is a signal that NRIX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 63 similar cases where NRIX's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

NRIX's RSI Indicator ascending out of oversold territory

The RSI Oscillator for NRIX moved out of oversold territory on August 21, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

NRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NRIX as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

NRIX moved below its 50-day moving average on July 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NRIX crossed bearishly below the 50-day moving average on July 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NRIX entered a downward trend on August 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.631) is normal, around the industry mean (19.660). P/E Ratio (0.000) is within average values for comparable stocks, (54.828). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.654). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (8.606) is also within normal values, averaging (303.787).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NRIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. NRIX showed earnings on July 09, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1700 Owens Street
Phone
+1 415 660-5320
Employees
284
Web
http://www.nurixtx.com